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HYPERRESPONSIVENESS of the airways to nonspecific
stimuli is a characteristic feature of asthma.
Airway responsiveness is usually characterized in
terms of the position and shape of the dose-
response curve to methacholine (MDR). In the
study we have investigated the influence of fluti-
casone propionate (FP), a topically active gluco-
corticoid, on arachidonic acid (AA) metaboHtes in
broncho-alveolar lavage (BAL) fluid (i.e. TxB2,
PGE2, PGD2, 6kPGFI and LTC4) on the one hand
and MDR curves on the other hand. The effect of
FP was studied in a randomized, double-blind,
placebo-controlled design in 33 stable non-
smoking asthmatics; 16 patients received FP (500
g b.i.d.) whereas 17 patients were treated with
placebo. We found that the forced expiratory
volume in ls (FEV1 fro predicted) increased, the
log2PC20 methacholine increased and the plateau
value (% fall in FEVl) decreased after a 12 week
treatment period. No changes in AA-metabolites
could be determined after treatment except for
PGD2 which decreased nearly significantly
(p=0.058) within the FP treated group, whereas
the change of PGD2 differed significantly (p
0.05) in the FP treated group from placebo. The
levels of the other AA metabolites (i.e. TxB2, PGE2,
6kPGFI= and LTC) remained unchanged after
treatment and were not significantly different
from the placebo group. Our results support the
hypothesis that although FP strongly influences
the position, the shape and also the maximum
response plateau of the MDR curve, this effect is
not mainly achieved by influence on the level of
AA metabolites. Other pro-inflammatory factors
may be of more importance for the shape of the
MDR curve. It is suggested that these pro-inflam-
matory factors are downregulated by FP.
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Bronchial hyperresponsiveness (BHR), a prom-
inent feature of asthma, can be demonstrated by
generating dose-response curves through inhala-
tion of histamine or methacholine. Usually these
curves are sigmoid in shape, with a distinct
threshold, a linear slope in the midpart and a
maximum response. The provocative concentra-
tion producing a fall of 20% in the FEV1 (PC20) is
called the sensitivity, whereas the slope in the
midpart is defined as reactivity. The plateau value
of the curve reflects mammal airway narrowing.
Asthmatics not only show a leftward shift of
the dose-response curve, but also higher or
even unmeasurable plateau values as compared
with normal subjects. Activation of inflammatory
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cells and release of mediators, such as arachi-
donic acid (AA) metabolites in bronchoalveolar
lavage (BAL) fluid, may be present in asthma and
may influence the shape of the methacholine
dose-response (MDR) curve by enhancing
BHR.2-5
Although it is known that anti-inflammatory
therapy with inhaled corticosteroids (ICS) shifts
the dose-response curve to the right and
reduces the maximum response,7 data concern-
ing the influence of inflammatory mediators such
as AA metabolites are scarce.4 One may expect
that inhibition of their release by ICS may lead to
a change in the shape of the dose-response
curve. Therefore, in asthmatics, we tested the
hypothesis that fluticasone propionate (FP), a
new topically active ICS, downregulates AA
(C) 1996 Rapid Science Publishers
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metabolites in BAL fluid on the one hand, and Longfunction testing:
influences the different characteristics of the
MDR curves on the other hand. We also investi- Inclusion measurements. FEV1 was derived from
gated the relation between the various para- a maximal expiratory flow volume curve, using a
meters studied, pneumotachometer (Jaeger, WCrzburg,
Gel’many). Reversibility was tested 20 min after
d four separate inhalations of 250 l.tg of terbuta-line sulphate. A histamine provocation test was
Subjects.. Thirty-three nonsmoking atopic asth- performed with a 2 min tidal breathing methods
matics (23 male, median age 26 years, range using a nose clip. Reference values of lung
18 to 56 years) fulfilled the following criteria: function measurements are according to Quanjer
PC20 histamine < 8 mg/ml and > 9% revers- et al.9
ibility in forced expiratory volume in i s (FEV1),
relative to baseline, following inhalation of 1000 Study measurements. Methacholine was adminis-
tg terbutaline sulphate. Atopy was defined by at tered according to a standardized tidal breathing
least one positive skin-prick test to a panel of 16 method. Dose-response curves were obtained
common aero-allergens in the presence of a after inhalation of doubling concentrations of
positive histamine and negative control, acetyl-[-methylcholine bromide (0.03-256 mg
In the month preceding the run-in period, m1-1 in normal saline). Methacholine and not
patients were only allowed to take inhaled short- histamine was chosen as bronchoconstrictor
acting 2-agonists, on an as needed basis. All stimulus during the study, because it produces
other medication was stopped. Patients with a less systemic side effects when given in high
history suggesting respiratory infection or exacer- doses. Solutions of methacholine were stored
bation of asthma in the month prior to the study at 4C and administered at room temperature.
were excluded. All subjects gave informed The aerosols were generated by a De Vilbiss 646
written consent to the study, which was nebulizer (output 0.13 ml min-) and inhaled by
approved by the local ethics committee, tidal breathing for 2 min. The response to
methacholine was measured as change in FEV
Study design: The study was of a randomized, expressed as percentage of initial value and
double-blind, placebo-controlled design. After a related tO log2 dose. A test was interrupted if the
run-in period of 2 weeks there was a 12 week FEV1 fell by more than 60%, or if unpleasant
treatment period. During the 2 week run-in side effects or dyspnoea compelled the patient
period patients discontinued use of their usual to stop.
inhaled bronchodilator which was replaced with A recently developed and validated sigmoid
salbutamol 400 l.tg as dry powder via the Disk- Cumulative Gaussian Distribution (CGD) func-
haler four times daily. Up to four additional tion was fitted to the data.2 Although the sensi-
doses were allowed as needed. Baseline data tivity (1og2PC20) was obtained by linear
were obtained on two visits with an inteeeal of 2 interpolation of two successive log2 concentra-
weeks. At each baseline visit that consisted of tion values,8 the plateau value and the reactivity
two morning or afternoon sessions, a flow (defined as slope in the 50% point of the CGD
volume curve was constructed, bronchodilator function) were obtained as best fit parameters.
response was measured and a provocation test Hence, reactivity denotes the percentual change
was carried out. At the second baseline visit, from baseline FEV per doubling dose (%/dd) in
intradermal skin testing was performed. When the steepest point of the CGD function. Details
patients fulfilled the mentioned criteria, broncho- of the fit procedure and validation of the CGD fit
alveolar lavage (BAL) was performed 1 week are according to Aerts eta/. 12
after the last baseline visit. Following the BAL,
the patients were randomized to treatment with Bronchoalveolar lavage: Fibre-optic broncho-
either inhaled 500 g FP or placebo, both given scopy was performed according to guidelines of
twice daily as dry powder via the Diskhaler. the American Thoracic Society. After pre-
Patients continued salbutamol 400 g four times medication with inhaled terbutaline and atro-
a day, but could take up to four additional doses pine i.m., the bronchoscope (Olympus B1 IT
as needed for symptomatic relief. 10, Tokyo, Japan) was introduced into the
After 6 and 12 weeks of treatment patients lateral segment of the middle lobe under local
attended the clinic on which occasion a MDR curve anaesthesia and placed in wedge position. BAL
(see below)was performed. After 13 weeks, 1 was performed with four 50-ml aliquots of
week after the last dose-response curve was sterile phosphate buffered saline (PBS)warmed
obtained, the BAL procedure was repeated, to 37C. The fluid was then immediately aspir-
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ated by gently suctioning with -40 cm H20 into Results
a siliconized specimen trap placed on melting
ice and transported to the laboratory for pro- Sixteen patients (12 men) were randomized
cessing and analysis, into the FP group and 17 patients (11 men) into
The BAL fluid was centrifuged at 400 x g for the placebo group. Baseline values such as FEV1,
5 min at 4C. The supernatants were decanted reversibility and PC20 histamine were not sig-
and stored. The cell pellets were then washed in nificantly different between the groups on entry
PBS supplemented with 0.5% heat-inactivated to the study (Table 1). Thirty-one of the 33 sub-
bovine serum albumin (BSA). For total leukocyte jects completed the study. One patient receiving
numbers in BAL fluid, cell suspensions were placebo and one receiving FP were withdrawn
counted in a Coulter Counter and viability was after experiencing a pulmonary exacerbation.
assessed by cellular exclusion of trypan blue. Data of these two patients have not been inclu-
Cytospin preparations were stained with May- ded in the analysis.
Grnwald-Giemsa stain, and the differential Mean values for FEV1 (as % predicted), sensi-
counts were performed by counting at least 500 tivity (logiPCi0methacholine), reactivity (%/dd)
cells, and plateau (% fall in FEVl) before and after
Determination of AA metabolites: Immediately
after the BAL procedure, 20 ml of supernatant
was processed on C18 SepPak cartridges
treatment are shown in Table 2. No statistical sig-
nifican differences were present between the
indices before treatment. In the FP group sig-
nifican changes occurred after 12 weeks with
(Millipore, Bedford, USA) as described pre- respect to means of PC20 (an increase of 3.6
viously,14 eluated with 2.5 ml methanol and doubling doses), plateau value (from 58.8% at
randomization to 36.5% fall in FEV1) and base-stored at-80C until analysis. Samples of 200 btl line FEV1 (from 82.9% to 91.0%) in contrast toBAL eluted fluid were pipetted into poly- the placebo group. Changes for reactivity werepropylene tubes and dried with a Savant sample less marked.
concentrator. After dissolving in 300 gl assay Mean values for AA metabolites and total cellbuffer, levels of thromboxane 82 (TxB2) were
determined by means of a [H] RIA with recovery before and after treatment are pre-
sented in Table 3. Values were comparable in
antisera from Advanced Magnetics Inc. (Cam-
bridge, MA) and [H] labelled compounds from
Amersham International (Buckinghamshire, UK).
Levels of prostaglandin PGD2 and PGE2 were
determined with commercially available [H] kits
(Amersham, UK) and 6kPGFI with a [1251] RIA
kit (Du Pont de Nemours, Dreieich, Germany),
according to the manufacturer’s instructions.
Leukotriene C4/D4/E4 (EWe4) was measured at
room temperature in a microtitre enzyme immu-
noassay according to protocol (Biotrak, Amer-
sham, UK).
both treatment groups on entry to the study.
Significant results were found only for PGD2; it
decreased nearly significantly in the FP group
from 25.8 (S.E.M. +__ 10.9) to 7.3 (S.E.M. _+
1.8)(p 0.059), whereas its change in the FP
group differed significantly from that in the
placebo group (p 0.05) after 12 weeks of
treatment.
We also determined if there were correlations
Table 1. Baseline characteristics of the study patients
Statistical analysis: The paired t-test was used to
Characteristics Fluticasone Placebo
analyse within-treatment changes in FEV and
bronchial hyperresponsiveness. The unpaired t- n 6 17
test was used for comparisons between groups. Sex M/F 12/4 11/6
Age (years) 28.4 (10.8) 34.5 (13.5)In case of non-normally distributed variables FEVl (% predicted) 84.2 (15.4) 86.0 (17.6)
non-parametric tests were used (paired and Reversibility" 15.5(7.8) 18.1 (14.3)
unpaired Wilcoxon test). A/value smaller than PC2oH* mg/ml 0.71 (0.59) 0.88 (0.87)
Iog2PC2oH 1.12 (1.62) -0.96 (1.70)0.05 was supposed to indicate statistical sig- Plateau value 58.8 (19.8) 50.8 (12.7)
nificance. Spearman-Rank correlations (re) were Reactivity (%/doubling dose) 11.6(5.3) 9.4(3.7)
used for testing intercorrelation between Total IgE (IU/ml) 311 (288) 299 (289)
outcome variables wi[hin the groups. Values of All values are expressed as mean
_
standard deviation (between
rsl > 0.6 were considered relevant only if they brackets).
*Reversibility: change in FEV1 expressed as % baseline, after 000 Igreached a significance level (p < 0.01). Group terbutalinesulphate.
means and standard error of the mean (+ rpC2oH=PC2ohistamine;Iog2PC2oH-Iog2PC2ohistamine.
S.E.M.) at the various time points were calcu- Plateau value expressed as fall in FEV1.No statistical significant differences were present between the treatment
lated, groups.
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Table 2. MDR-curve indices of the study patients
Lung function parameters
Fluticasone Placebo
Before treatment After 12 weeks Before treatment After 12 weeks
FEV1 (% predicted) 82.9 (4.1) 91.0 (3.8)*,** 82.9 (4.2) 80.1 (5.1)
Iog2PC2oM 0.18 (0.56) 3.77 (0.72)*,** -0.05 (0.74) 0.26 (0.46)
reactivity (%/doubling dose) 11.6 (1.3) 9.0 (1.8) 9.4 (0.9) 10.8 (1.0)
plateau (% fall in FEVl) 58.8 (4.9) 36.5 (4.1)*,** 50.8 (3.2) 48.8 (3.6)
All values are expressed as mean +_ S.E.M. (between brackets).
+log2PC2oM Iog2PC2o methacholine.
No statistical significant differences were present between the indices before treatment. Significance of changes during treatment are
indicated (*p < 0.05). Also significant differences in changes between the treatment groups are indicated (** p < 0.01).
Table 3. AA metabolites and cell levels in BAL fluid
Fluticasone Placebo
AA metabolites Before treatment After 12 weeks Before treatment After 12 weeks
TxB2 34.1 (4.2) 36.1 (4.2) 32.2 (4.8) 29.2 (3.8)
PGE2 1.3 (0.6) 10.2 (0.8) 1.3 (0.6) 1.3 (0.9)
PGD2 25.8 (10.9) 7.3 (1.8) 15.4 (4.0) 17.9 (4.5)
6kPGF= 4.0 (0.4) 3.2 (0.2) 4.2 (0.4) 3.3 (0.5)
LTC4 12.1 (3.8) 6.7 (2.0) 11.6 (4.1) 12.1 (3.0)
Total cell recovery x 106 10.8 (0.08) 15.2 (0.11) 12.4 (0.09) 11.4 (0.06)
All values are expressed as mean -t- S.E.M. (between brackets).
AA arachidonic acid; TXB2 thromboxane B2; PGE2 prostaglandin E2; PGD2 prostaglandin 02; 6kPGFI= 6 keto-prostaglandin FI=;
LTC4 leukotriene C4. The decrease in PGD2 within the fluticasone group was nearly significant (p 0.058). With respect to the difference
in changes between both groups only the change in PGD2 differed significantly (p 0.05) between the fluticasone and the placebo group.
between changes in either treatment group and
investigated whether these correlations were dif-
ferent between the treatment groups. In neither
of the treatment groups, however, relevant and
significant correlations were found between the
parameters investigated.
Discussion
We showed that after 12 weeks of treatment flu-
ticasone propionate (FP) significantly decreased
both sensitivity to methacholine and the maximal
airway narrowing response, whereas it sub-
stantially decreased PGD2 levels in BAL fluid. The
change in PGD2 level after treatment with FP was
significantly larger than the change in the
placebo group. We were unable, however, to
demonstrate a correlation between these changes
in sensitivity and plateau level with the change in
PGD2 or one of the other arachidonic acid (AA)
metabolites.
To date, several studies have described the
relation between airway inflammation, the sub-
sequent release of AA metabolites and bronchial
responsiveness. It has to be kept in mind,
however, that the bronchial responsiveness in
those studies has never been measured by the
entire methacholine dose-response (MDR)
curve. Bronchial responsiveness as determined
by the MDR curve is defined as the sensitivity of
the airways to a wide variety of nonsensitizing
bronchoconstricting stimuli. It has been demon-
strated that the curves from asthmatics could be
differentiatied from those of normal subjects by
their position, slope and maximal response.
MDR curves in asthma have a steeper slope and
a higher maximal response at high doses of
methacholine as compared to normal subjects.
A leftward shift of the cueee can be regarded as
being the result of any augmentation of airway
narrowing stimuli (i.e. preiunctional mechanisms)
such as activation of inflammatory cells and
release of mediators such as AA metabolites.15-17
An upward movement of the plateau is the result
of an increase in the response of the effector
organ (i.e. postjunctional mechanisms) such as
smooth muscle contraction and swelling of the
airway wall. To our knowledge this is the first
study that investigated the possible correlation of
sensitivity, reactivity and plateau value of the MDR
curve on the one hand and AA metabolites in
BAL fluid on the other hand. However, as men-
tioned above, we could not demonstrate such a
correlation, nor could we find a significant corre-
lation between the FP-induced decrease in BHR
and the levels of AA metabolites in BAL fluid.
This suggests that in addition to AA metabolites
other factors, such as epithelial damage, numbers
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of eosinophils and neutrophils in BAL fluid, pla- In support of this hypothesis, Bel et al.
telet activating factor, histamine and major basic demonstrated that inhaled LTD4 not only caused
protein, are important as was shown by other a higher maximal response plateau than metha-
authors.18-22 Our findings are in contrast with choline, but also increased the maximal response
those of Oosterhoff et al. who demonstrated that to methacholine for at least 3 days. These find-
the levels of PGD2 in BAL fluid are inversely cor- ings could be prevented by the administration of
related with the PC20 histamine. A possible inhaled steroids.
explanation for this observed discrepancy could Tamaoki et al.34 found that prednisone
be the difference in treatment period; they found reduced the synthesis of eicosanoids by stimu-
a correlation between AA metabolite levels and lated macrophage-rich BAL-fluid cells in vitro.
PC20 histamine after long-term treatment (2.5 However, Dworski et al. showed that oral pred-
years) with ICS. nisone reduced symptoms but had no significant
Prostaglandins D2 and Fia thromboxane B2, effect on BAL fluid eicosanoid levels in vivo.5 In
and leukotrienes B4, C4 and D4 are potent pro- line with this study, we also failed to find a
inflammatory mediators with a wide variety of reduction in AA metabolites in BAL fluid. Only
biological activities, including smooth muscle PGD2 appeared to be nearly significantly lower
contraction, mucus hypersecretion and leukocyte (p 0.058) in FP treated subjects, whereas the
activation.2-25 In a previous study we demon- change in PGD2 before and after 12 weeks of
strated that the subclinical inflammation in treatment with FP was significantly larger (p
smokers was associated with higher levels of 0.05). It has been demonstrated in canine airway
PGF2 and TxB2 in BAL fluid as compared to smooth muscle that PGD2 prejunctionally aug-
non_smokers.4 It is conceivable that the ments the parasympathetic contractile
increased amounts of PGF2cz and TxB2 are due to response.4 Stimulation of asthmatics with PGD2
activation of alveolar macrophages in the airways significantly increased the reactivity to histamine
of smokers. PGF2a and TxB2 induce airway and methacholine.2 It was suggested that
secretion, constrict isolated human airways and enhanced cholinergic tone underlied these find-
increase the sensitivity to contractile stimuli.26 In ings. Beasley et al. demonstrated that PGD2 and
a study of Wardlaw et al. levels of leukotrienes its metabolite 9z,l l[-PGF2 caused a marked
(LTC4 and LTB4) were higher in BAL fluid of increase of methacholine induced bronchocon-
symptomatic asthmatics with bronchial hyperre- striction that could only partially be prevented by
sponsiveness as compared to asymptomancs."27 an anticholinergic.2 In addition, several studies
Although their methodology to measure AA showed that allergen challenge resulted in a
metabolites differed from ours, which makes marked increase in prostaglandin levels in BAL
comparison of the results rather difficult, the fluid.<v This suggests that PGD2 may augment
levels of LTC4 in our study appeared to be equal the histamine or methacholine induced hyper-
to those of the asymptomatics in their study. The responsiveness. The effects of prostaglandins on
fact that these levels were already low at the start reactivity or plateau value is unknown, because
of the study may explain why we were unable to none of the above mentioned authors investi-
demonstrate an effect of treatment, gated the entire MDR curve and a possible rela-
Other workers carried out allergen challenge tion of prostaglandins with reactivity or plateau
and measured BAL fluid and urinary levels of value.
LTE4, the end product of enzymatically converted In our study PGD2 levels in BAL fluid of asth-
LTC4 and LTD4. It was found in asthmatics that matics substantially decreased after treatment
the basal levels of leukotrienes were not elevated, with FP. Since PGD2 is a product derived from
but increased in vivo after allergen chal- mast cells and to a lesser extent from alveolar
38 39lenge.28-1 Christie et al. showed that children macrophages, it may be concluded from our
with atopic asthma who were resident at high results that ICS, particularly, downregulate mast
altitude, exhibit a fall in FEV and an increase in cells to produce PGD2 although the influence on
airway responsiveness to histamine upon visiting alveolar macrophages is not excluded.
regions at sea level. This was associated with a In conclusion, in our study we demonstrated
three-fold increase in urinary LTE4 excretion.2 that BHR as determined by the MDR curve is
Thus it seems that in asymptomatic asthma downregulated by FP. Although FP strongly influ-
patients or asthmatics with minor symptoms, the ences the position, the shape and also the
levels of leukotrienes in BAL fluid are not maximum response plateau of the MDR curve, it
increased. Upon stimulation (tobacco smoke, did not influence levels of AA metabolites in BAL
allergen challenge or visit to sea level), however, fluid except for PGD2. Our results indicate that
leukotriene levels rapidly increase resulting in the effect of FP on BHR is not achieved mainly
bronchial hyper-responsiveness, by its influence on the level of the AA metabo-
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lites. It is suggested that other pro-inflammatory
factors are of more importance for the shape of
the MDR curve.
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